Provided by Tiger Fintech (Singapore) Pte. Ltd.

SELLAS Life Sciences Group Inc.

1.41
+0.01000.71%
Post-market: 1.460.0500+3.55%19:59 EDT
Volume:2.75M
Turnover:3.83M
Market Cap:128.09M
PE:-2.79
High:1.45
Open:1.43
Low:1.35
Close:1.40
Loading ...

Sellas $25M registered direct offering priced at $1.27 per share and warrant

TIPRANKS
·
29 Jan

Sellas Life Sciences Group Announces $25 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
29 Jan

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire
·
29 Jan

SELLAS Life Sciences Shares Fall; Interim Trial Results on Acute Myeloid Leukemia Treatment Issued

MT Newswires Live
·
24 Jan

Sellas Life Sciences announces IDMC completed interim analysis of REGAL trial

TIPRANKS
·
23 Jan

Sellas Life Sciences Group Inc: 80% of Randomly Selected Regal Gps Patients Showed a Specific T-Cell Immune Response

THOMSON REUTERS
·
23 Jan

Sellas Life Sciences Group: Idmc Has Recommended That Trial Continue Without Modifications

THOMSON REUTERS
·
23 Jan

Sellas Life Sciences Announces Positive Outcome of Interim Analysis for Its Pivotal Phase 3 Regal Trial of Gps in Acute Myeloid Leukemia

THOMSON REUTERS
·
23 Jan

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

GlobeNewswire
·
23 Jan

BRIEF-Sellas Life Sciences Says Full Topline Phase 2 Data In Acute Myeloid Leukemia And FDA Regulatory Review Expected In 1H 2025 For SLS009

Reuters
·
08 Jan

Sellas Life Sciences Group Inc: Full Topline Phase 2 Data in Acute Myeloid Leukemia and FDA Regulatory Review Expected in 1H 2025 for Sls009

THOMSON REUTERS
·
08 Jan

SELLAS Announces Key Business Objectives for 2025

GlobeNewswire
·
08 Jan

SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET

GlobeNewswire
·
02 Jan

Prediction: NASA's Big Moon Mission Hiccup Will Cost Boeing Another $4 Billion in 2025

Motley Fool
·
15 Dec 2024

Sellas Life Sciences Triggers Interim Analysis in Phase 3 Regal Trial of Gps in Acute Myeloid Leukemia

THOMSON REUTERS
·
10 Dec 2024

Sellas Life Sciences Group: Regal Independent Data Monitoring Committee to Perform Interim Analysis in Jan 2025

THOMSON REUTERS
·
10 Dec 2024

Sellas Life Sciences Group: Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating Interim Analysis

THOMSON REUTERS
·
10 Dec 2024

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

GlobeNewswire
·
10 Dec 2024

Sellas Life Sciences Group Inc - Sls009 Well-Tolerated With No New Safety Signals Observed

THOMSON REUTERS
·
09 Dec 2024

Sellas Announces Positive Overall Survival and Overall Response Rate Data From the Phase 2 Trial of Sls009 in R/R Aml

THOMSON REUTERS
·
09 Dec 2024